The Discounted Cash Flow (DCF) valuation of Protagonist Therapeutics Inc (PTGX) is (49.35) USD. With the latest stock price at 41.60 USD, the upside of Protagonist Therapeutics Inc based on DCF is -218.6%.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 7.5% | 6.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (122.73) - (31.21) | (49.35) |
| Upside | -395.0% - -175.0% | -218.6% |